Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Ranking of “Purchase” by Analysts


According to reports from Marketbeat.com, Tandem Diabetes Care, Inc. (NASDAQ: TNDM) shares have been given a consensus rating of “Buy” by the fourteen rating agencies that cover the company. Five investment analysts have rated the stock with a hold rating and nine with a buy rating. The average target price for a year among brokers who updated their coverage for the stock last year is $ 116.64.

Several equity analysts recently made comments on TNDM stocks. Wells Fargo & Company lowered Tandem Diabetes Care’s shares from an “overweight” rating to a “balanced” rating and set a price target of $ 105.00 for the company. in a research report on Tuesday, December 15th. SVB Leerink raised its price target for Tandem Diabetes Care from USD 120.00 to USD 130.00 and gave the company a “Market Perform” rating in a research note on Friday, November 6th. Raymond James raised its price target for Tandem Diabetes Care from US $ 116.00 to US $ 124.00 and rated the company “Outperform” in a research note on Friday, November 6th. Piper Sandler raised its price target for Tandem Diabetes Care from US $ 125.00 to US $ 132.00 and gave the company an “Overweight” Research Note on Friday, November 6th. Eventually, Zacks Investment Research downgraded Tandem Diabetes Care from a “Buy” rating to a “Hold” rating and set a price target of $ 104.00 for the company. in a research report on Monday, January 25th.

In other news, director Kim D. Blickenstaff sold 13,598 shares in a transaction that occurred on Tuesday, December 15. The stock was sold at an average price of $ 92.48 for a total transaction of $ 1,257,543.04. The transaction was announced in a filing with the Securities & Exchange Commission, which can be accessed via this link. In addition, director Kim D. Blickenstaff sold 16,802 shares in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $ 106.88 for a total value of $ 1,795,797.76. The disclosure for this sale can be found here. Insiders sold a total of 80,400 shares in the company last quarter, valued at $ 7,833,864. Corporate insiders own 6.00% of the company’s stock.


The cryptocurrency market is currently exploding in value … Bitcoin has broken through $ 30,000 … And dozens of cryptos are up more than 1,000% … If you are ready to take advantage of this massive boom, legendary crypto investor Matt McCall has just released a new free report, “3 Cryptos to Beat Bitcoin”.

Several hedge funds and other institutional investors recently bought and sold shares in the company. Manchester Financial Inc. increased its stake in Tandem Diabetes Care 48.4% in the fourth quarter. Manchester Financial Inc. now owns 371 shares of the medical device company, valued at $ 35,000, after purchasing an additional 121 shares during the period. US Bancorp DE increased its stake in Tandem Diabetes Care by 16.4% in the fourth quarter. US Bancorp DE now owns 795 shares in the medical device company valued at $ 76,000 after purchasing an additional 112 shares during the period. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Tandem Diabetes Care for $ 148,000 in the third quarter. Zeke Capital Advisors LLC acquired a new stake in Tandem Diabetes Care worth $ 208,000 in the third quarter. Finally, the IBM Retirement Fund acquired a new stake in Tandem Diabetes Care for $ 218,000 in the third quarter. Hedge funds and other institutional investors own 88.60% of the company’s shares.

NASDAQ TNDM opened at $ 100.36 on Friday. Tandem Diabetes Care has a 52-week low of $ 43.69 and a 52-week high of $ 123.74. The company has a market cap of $ 6.11 billion, a P / E of -123.90, and a beta of 0.31. The company has a quick rate of 4.94, a current rate of 5.61, and a leverage ratio of 0.61. The company has a 50-day moving average price of $ 94.29 and a 200-day moving average price of $ 102.49.

Tandem Diabetes Care (NASDAQ: TNDM) last released its quarterly results on Thursday, November 5th. The medical device company reported earnings per share of $ 0.15 for the quarter, missing the Thomson Reuters consensus estimate of $ 0.08 by $ 0.07. Tandem Diabetes Care had a negative net margin of 11.10% and a negative return on equity of 10.98%. The company posted revenue of $ 123.60 million for the quarter, compared to analyst expectations of $ 115.16 million. For the same period last year, the company had earnings per share of $ 0.09. Tandem Diabetes Care sales increased 30.6% for the quarter compared to the prior-year quarter. Equity analysts assume that Tandem Diabetes Care will achieve an EPS of -0.35 this year.

Tandem Diabetes Care company profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and markets a variety of products for people with insulin dependent diabetes in the United States. The company’s flagship is the t: slim X2 insulin delivery system, a pump platform that includes the t: slim X2 pump, the disposable 300-unit insulin cartridge and an infusion set.

Recommended Story: What Are the Different Types of Leveraged Buyouts?

Analyst Recommendations for Tandem Diabetes Care (NASDAQ: TNDM)

This instant message alert was generated through narrative science technology and financial data from MarketBeat to give readers the fastest, most accurate coverage possible. This story has been reviewed by the editorial staff of MarketBeat prior to publication. Please send questions or comments about this story to [email protected]

20 stocks Wall Street analysts love the most

Every trading day, between 500 and 800 new recommendations and research reports are published by sell-side equity research analysts. There are between 300 and 500 brokers and research houses providing ratings, price targets and recommendations, as well as more than 5,000 stocks around the world that are regularly covered by research analysts.

MarketBeat has tracked more than 170,000 different analyst recommendations in the past 12 months alone. Given the volume of rating changes that occur each day, it can be difficult to sift through the noise.

Analysts don’t always get the correct “buy” rating, but it pays to take a close look when more than a dozen different analysts from different brokers and research firms “strong buy” – and “buy” – the same stock. Give rating.

This slideshow lists the 20 companies that have received the highest average analyst recommendations from Wall Street equity analysts over the past 12 months.

Check out the “20 Stock Wall Street Analysts Love The Most”.